NDAORALTABLET
Approved
Jul 1947
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
PROPYLTHIOURACIL (propylthiouracil) by Pfizer is thyroid hormone synthesis inhibitors [moa]. First approved in 1947.
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Propylthiouracil (PTU) is an oral thyroid hormone synthesis inhibitor approved in 1947 for the treatment of hyperthyroidism. It works by blocking the enzyme peroxidase, which is essential for thyroid hormone production, thereby reducing circulating thyroid hormone levels. PTU is a small-molecule antithyroid agent used primarily in Graves' disease and thyroiditis.
LOE Approaching
Legacy product approaching loss of exclusivity with low competitive pressure (30%), indicating modest team size and defensive market strategy.
Mechanism of Action
Thyroid Hormone Synthesis Inhibitors
Pharmacologic Class:
Thyroid Hormone Synthesis Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PTU offers limited growth opportunities given its approaching loss of exclusivity and mature lifecycle stage. Roles focus on defensive strategies, patient access programs, and operational efficiency rather than market expansion or innovation.
Product Manager (Specialty)Commercial Operations Manager
Worked on PROPYLTHIOURACIL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.